Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Automated urIne Flow Detection to Reduce Errors and Nursing Workload (AiDe-RN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03636113
Recruitment Status : Active, not recruiting
First Posted : August 17, 2018
Last Update Posted : December 5, 2019
Sponsor:
Collaborator:
RenalSense Ltd
Information provided by (Responsible Party):
John Kellum, University of Pittsburgh

Brief Summary:
This study is an observational study which seeks to examine a) the accuracy of the Clarity Renal Monitoring System (Clarity RMS)® sensor kit at the bedside compared to manual urine output monitoring, b) total time/effort per patient with and without the device, c) the ease of use, clinical acceptance, and d) preliminary data on the detection of AKI using the Clarity RMS® sensor kit compared to standard care

Condition or disease Intervention/treatment
Acute Kidney Injury Kidney Injury Device: Clarity RMS Electronic Sensor

Detailed Description:

The majority of physiological parameters of the patient in a critical care setting today are electronically monitored. Automation of these parameters not only reduces workload and human error, but also may provide alarms and warnings when these parameters fall below a pre-set range. Currently, urine output may be the most relevant physiological parameter that still involves manual recordings in the critical care setting.

In 2004, The Acute Dialysis Quality Initiative (ADQI), a group of experts in kidney dysfunction, proposed the RIFLE criteria for acute kidney injury (AKI). They describe Risk, Injury and Failure severity classes and Loss and End stage Kidney Disease outcome classes. The severity grades are based on serum creatinine, urinary output or both. More recently the Acute Kidney Injury Network (AKIN) stages for kidney injury added smaller relative increases in serum creatinine levels to classify patients at risk. Since the classification has been proposed, tens of thousands of patients have been involved in studies validating the RIFLE and AKIN criteria as a classification system for AKI. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) AKI clinical practice guideline published in 2012 adopted modified RIFLE/AKIN criteria for classification of AKI. Studies using these criteria report kidney injury in Intensive Care Units at incidences of 50-70%.

Serum creatinine is considered a gold standard for measurement of kidney function; however, increases in its levels are seen only after there is approximately 50% loss of renal function, hindering early and sensitive detection of kidney injury and thus appropriate treatment. Many individual factors of the hospitalized patient can also interfere with the accuracy of changes in levels of serum creatinine, making this a less than ideal marker for kidney injury.

While urine output is an easily available biomarker of kidney function, only a small percentage of current studies that incorporate RIFLE and AKIN criteria utilize urinary output as a diagnostic criterion for AKI. Fluid overload has been shown to be a factor of increased mortality and further AKI. Sodium and water overload are common complications of fluid resuscitation, an initial treatment in many cases of AKI. Studies have shown that oliguria for three or more days, and a higher percentage of days with fluid overload after an initial AKI diagnosis is made, are two proven independent predictors for the development of sepsis post-AKI. In a recent study of periods of oliguria as a predictor of higher mortality in critically ill patients the authors note "treating urine flow as a continuous physiological variable instead of an interval parameter that is currently a challenge to measure accurately would provide more time points for the detection of AKI… in clinical practice, the hourly urine flow provides more precision for risk assessment and establishes early time for interventions." Current practice for measuring urine output in most hospitals worldwide involves manual recording on an hourly basis at best, and often one or two times per shift. It is essential to develop updated easy-to use- tools and systems for monitoring and managing patient fluid balance, for prevention and treatment of acute kidney injury and for patient survival. RenalSense has developed such a technology to enable online continuous monitoring of urine output and kidney function.

The current standard of care for urine output monitoring is the "manual" urometer. This approach is labor intensive, and prone to measurement error. An automated system would likely improve accuracy and reduce work load.

Layout table for study information
Study Type : Observational
Actual Enrollment : 33 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Automated urIne Flow Detection to Reduce Errors and Nursing Workload
Actual Study Start Date : July 11, 2018
Actual Primary Completion Date : December 28, 2018
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
ICU nurses -manual
Standard method of Urine Output monitoring
ICU nurses -automated
Device- Clarity RMS Electronic sensor
Device: Clarity RMS Electronic Sensor
The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours




Primary Outcome Measures :
  1. Accuracy of the Clarity RMS® electronic sensor [ Time Frame: 6 hours after ICU admission ]
    6-hour observation data, hourly urine output obtained from the EMR, and urine output monitoring captured by the Clarity RMS® electronic sensor



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
ICU Nurses
Criteria

Inclusion Criteria:

  • Male and Female ICU nurses
  • Caring for 1 or more patients in ICU with a Foley catheter in situ

Exclusion Criteria:

  • Nurse managing a patient who will be in ICU less than 4 hours
  • Nurse managing a patient who is not producing urine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03636113


Locations
Layout table for location information
United States, Pennsylvania
UPMC Presbyterian Hosptial
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
RenalSense Ltd
Investigators
Layout table for investigator information
Principal Investigator: John Kellum, MD University of Pittsburgh

Layout table for additonal information
Responsible Party: John Kellum, Professor & Vice Chair for Research, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03636113    
Other Study ID Numbers: PRO17030459
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: December 5, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases